• Change from baseline in total hip BMD [ Time Frame: Assessed at 12 and 24 months ] [ Designated as safety issue: No ]
• Change from baseline in lumbar spine (L1-L4) BMD [ Time Frame: Assessed at 24 months ] [ Designated as safety issue: No ]
• Change from baseline in bone formation markers [ Time Frame: Assessed at 6 and12 months ] [ Designated as safety issue: No ]
• Change from baseline in bone resorption and formation markers [ Time Frame: Assessed at 6 and 12 months ] [ Designated as safety issue: No ]
• Change from baseline in LDL-cholesterol [ Time Frame: Assessed at 12 months ] [ Designated as safety issue: No ]
• Change from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and serum triglycerides [ Time Frame: Assessed at 3, 6 and 12 months ] [ Designated as safety issue: No ]

• 1. Change from baseline in total hip BMD at 12 and 24 months
• 2. Change from baseline in lumbar spine (L1-L4) BMD at 24 months
• 3. Change from baseline in bone formation markers at 6 and 12 months
• 4. Change from baseline in bone resorption and formation markers at 6 and 12 months
• 5. Change from baseline in LDL-cholesterol at 12 months
• 6. Change from baseline in LDL-cholesterol at 3 and 6 months, and HDL-cholesterol, total cholesterol, and serum triglycerides at 3, 6, and 12 months

The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer and who are high or moderate risk of fragility fracture. It is also conducted to determine the effects of anastrozole on bone mineral density (BMD) and on bone metabolism in women at low risk of fragility fracture.

• Drug: Anastrozole
• Drug: Risedronate Sodium

• Experimental: High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
• Experimental: Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
• Experimental: Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum

Inclusion Criteria:

• Women defined as Postmenopausal
• Histologically proven operable invasive breast cancer
• Hormone-receptor-positive breast cancer

Exclusion Criteria:

• Clinical evidence of metastatic disease
• Bilateral hip fractures or bilateral hip prosthesis
• Receiving or received in last 12 months hormonal therapy for breast cancer, bisphosphonate therapy, oestrogens
• Malabsorption syndrome